Save

Extending the Time Window for Tenecteplase by Recanalization of Basilar Artery Occlusion in Posterior Circulation Stroke

PHASE2PHASE3RECRUITING

Patients presenting to the emergency department with an acute ischemic stroke due to basilar artery occlusion within 24 hours of stroke onset will be assessed to determine their eligibility for randomization into the trial. If the patient gives informed consent they will be randomised 50:50 using a central computerised allocation process to either standard of care (no intravenous thrombolytic treatment or intravenous alteplase 0. 9mg/kg) or tenecteplase 0.

25mg/kg before undergoing mechanical thrombectomy as required at treating clinician's discretion. The trial is Multi-arm, Multi-stage, prospective, randomised, open-label, blinded endpoint (PROBE) design with seamless phase 2b/3 transition if the intermediate endpoint (recanalization without symptomatic intracerebral hemorrhage) is met in analysis of the first 202 patients. Adaptive sample size re-estimation (Mehta and Pocock) will be performed when 240 patients have completed 3 month follow-up (minimum sample size 320, maximum sample size 688).

Simpliy with AI

Study details:

The study is a Multi-Arm Multi-Stage (MAMS), multiregional, multicentre, prospective, randomised, open-label, blinded endpoint (PROBE), controlled seamless phase 2b/3 trial (2 arm with 1:1 randomisation) with adaptive sample size recalculation in patients with stroke due to basilar artery occlusion. Stage 1 will use the surrogate outcome of recanalization without symptomatic intracerebral hemorrhage (sICH) to establish whether proceeding to Stage 2 is warranted. If results in the first n= 202 patients meet success criteria, the trial will seamlessly convert to a phase 3 design using modified Rankin scale 0-1 at 3 months as the primary outcome (minimum n=320 with interim sample size re-estimation at n=240, maximum sample n=688) using the Mehta and Pocock conditional power method.

Each regionally-based stratum will be pooled in the final analysis and analysed as a stratification by geographic region. Randomisation of patients within each stratum will be stratified by the investigator's intention to treat with mechanical thrombectomy (or not) and the investigator's intention to treat with alteplase intravenous thrombolysis should the patient be randomised to the control group (or not). Covariate adjusted minimum sufficient balance randomisation will then be applied to control for age, NIHSS and time from onset-to-randomisation (dichotomized as 0-6 hours vs 6-24 hours).

The primary objective of the study is to test the hypothesis that the thrombolytic tenecteplase (TNK, 0. 25mg/kg) ± mechanical thrombectomy administered within 24 hours after symptoms onset, is superior to current best practice (alteplase, rtPA, 0. 9mg/kg or standard care/no lysis ± mechanical thrombectomy) in achieving excellent functional outcome (mRS 0-1) or return to the premorbid modified Rankin Scale at 90 days in patients with acute ischemic stroke due to basilar artery occlusion.

Estimated study duration is 5 years. Patients will participate in the trial for 12 months.

Simplify with AI

Eligibility criteria

Researchers look for people who fit a certain description, called eligibility criteria. See if you qualify.

Inclusion criteria

Patients presenting with posterior circulation ischemic stroke symptoms due to partial or complete basilar artery occlusion within 24 hours from symptom onset (or clinical deterioration/coma) or the time the patient was last known to be well.

Patient's age is ≥18 years

Presence of basilar artery occlusion, proven by CT Angiography or MR Angiography. Basilar artery occlusion is defined as 'potentially retrievable' occlusion at the basilar artery. This can be a partial or complete occlusion.

Premorbid mRS ≤3 (independent function or requiring only minor domestic assistance and able to manage alone for at least 1 week).

Local legal requirements for consent have been satisfied.

Exclusion criteria

Intracerebral hemorrhage (ICH) or other diagnosis (e.g. tumour) identified by baseline imaging.

Posterior circulation Acute Stroke Prognosis Early CT score (pc-ASPECTS) <7 on non-contrast CT, CT Angiography source images or DWI MRI.

Significant cerebellar mass effect or acute hydrocephalus.

Established frank hypodensity on non-contrast CT indicating subacute infarction.

Bilateral extensive brainstem ischemia.

Strong suspicion of underlying intracranial atherosclerotic disease (e.g diffuse arterial calcifications, basilar stenosis) or dissection which may require immediate neuro-interventional procedure with intracranial stenting and not benefit from intravenous thrombolysis at investigator's discretion.

Pre-stroke mRS of ≥4 (indicating moderate to severe previous disability).

Other standard contraindications to intravenous thrombolysis.

Contraindication to imaging with contrast agents.

Clinically evident pregnant women.

Current participation in another research drug treatment protocol.

Known terminal illness such that the patients would not be expected to survive a year.

Planned withdrawal of care or comfort care measures.

Any condition that, in the judgment of the investigator could impose hazards to the patient if study therapy is initiated or affect the participation of the patient in the study.

Simplify with AI

Eligibility

Age eligible for study : 18 and older

Healthy volunteers accepted : No

Gender eligible for study: All

Things to know

Study dates

Study start: 2021-11-29

Primary completion: 2026-08-01

Study completion finish: 2026-12-01

Study type

TREATMENT

Phase

PHASE2

PHASE3

Trial ID

NCT05105633

Intervention or treatment

DRUG: Tenecteplase

DRUG: Standard Care (which may include intravenous Alteplase)

Conditions

• Basilar Artery Occlusion

Image related to Basilar Artery Occlusion

Condition: Basilar Artery Occlusion
DRUG: Tenecteplase and other drugs
Newcastle, New South Wales, Australia and more
Sponsor: University of Melbourne

You may be eligible to participate in this trial based on your search. Check eligibility by answering some questions.

Are you running this trial? If you're a clinic or sponsor, you can claim this study. Claim or learn more.

Find a site

Closest Location:

John Hunter Hospital

Research sites nearby

Select from list below to view details:

John Hunter Hospital
Newcastle, New South Wales, Australia
Liverpool Hospital
Sydney, New South Wales, Australia
Princess Alexandra Hospital
Woolloongabba, Queensland, Australia
Royal Adelaide Hospital
Adelaide, South Australia, Australia

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Participant Group/Arm	Intervention/Treatment
EXPERIMENTAL: Intravenous tenecteplase (TNK) Patients will receive intravenous tenecteplase (0.25mg/kg, maximum 25mg, administered as a bolus over 5-10 seconds).	DRUG: Tenecteplase Genetically modified tissue plasminogen activator at a dose of 0.25mg/kg given as an intravenous bolus over 5-10 seconds.
ACTIVE_COMPARATOR: Standard Care (which may include intravenous Alteplase) Patients will receive standard of care (no intravenous thrombolytic treatment or intravenous alteplase 0.9mg/kg at the standard licensed dose of 0.9 mg/kg up to a maximum of 90mg, 10% as a bolus and the remainder as an infusion over 1 hour).	DRUG: Standard Care (which may include intravenous Alteplase) Patients will receive standard care which may include intravenous alteplase at the standard licensed dose of 0.9 mg/kg up to a maximum of 90mg, 10% as a bolus and the remainder as an infusion over 1 hour.

What is the study measuring?

Primary outcome

Primary Outcome Measure	Primary Outcome Description	Primary Outcome Time Frame
Modified Rankin Scale (mRS) 0-1 or return to baseline mRS at 90 days	Modified Rankin Scale (mRS) 0-1 (no disability) or return to baseline mRS (if baseline premorbid mRS 2-3) at 90 days	90 days

Secondary outcome

Secondary Outcome Measure	Secondary Outcome Description	Secondary Outcome Time Frame
Modified Rankin Scale 0-2 or return to baseline mRS at 90 days	Proportion of patients with Modified Rankin Scale 0-2 or return to baseline mRS at 90 days	90 days
Modified Rankin Scale 0-3 or return to baseline mRS at 90 days	Proportion of patients with Modified Rankin Scale 0-3 or return to baseline mRS at 90 days	90 days
Ordinal analysis of the mRS at 90 days	Ordinal analysis of the mRS, merging category 5-6, at 90 days	90 days
Early clinical improvement	Proportion of patients achieving early clinical improvement (reduction in acute - 72 hour NIHSS score of ≥8 or 72 hour NIHSS 0-1).	72 hours
Substantial reperfusion on initial digital subtraction angiography run prior to thrombectomy	Proportion of patients with complete occlusion at baseline who achieve eTICI 2b/3 on initial digital subtraction angiography run prior to thrombectomy.	Initial angiogram (day 0)
Quality of Life assessment (EQ-5D) - at 90 days and 12 months	Quality of Life assessment (EQ-5D) - at 90 days and 12 months	90 days and 12 months
Symptomatic intracerebral hemorrhage (sICH)	Proportion of patients with sICH defined as parenchymal hemorrhage type 2 (PH2), subarachnoid hemorrhage, and/or intraventricular hemorrhage within 36 of treatment, combined with a neurological deterioration of ≥4 points on the NIHSS from baseline, or leading to death.	36 hours
All-cause mortality within 90 days	All-cause mortality within 90 days	90 days
Modified Rankin Scale (mRS) 5-6 at 90 days	Proportion of patients with Modified Rankin Scale (mRS) 5-6 at 90 days (severe disability or death)	90 days

Frequently Asked Questions

Please note: some questions and answers are submitted by anonymous patients or using AI, and have not been verified by Clinrol

No questions submitted. Be the first to ask a question!

You may be eligible to participate in this trial based on your search.Apply for study

Are you running this trial? If you're a clinic or sponsor, you can claim this study.Claim this trial

References

Clinical Trials Gov: Extending the Time Window for Tenecteplase by Recanalization of Basilar Artery Occlusion in Posterior Circulation Stroke